MX364680B - Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d. - Google Patents

Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.

Info

Publication number
MX364680B
MX364680B MX2015016497A MX2015016497A MX364680B MX 364680 B MX364680 B MX 364680B MX 2015016497 A MX2015016497 A MX 2015016497A MX 2015016497 A MX2015016497 A MX 2015016497A MX 364680 B MX364680 B MX 364680B
Authority
MX
Mexico
Prior art keywords
oral administration
vitamin
pharmaceutically acceptable
acceptable salt
ibandronic acid
Prior art date
Application number
MX2015016497A
Other languages
English (en)
Other versions
MX2015016497A (es
Inventor
Pedro Silva Serra João
Maria Soares Isabel
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50943510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX364680(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of MX2015016497A publication Critical patent/MX2015016497A/es
Publication of MX364680B publication Critical patent/MX364680B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica sólida mejorada para administración oral que comprende ácido ibandrónico o una sal farmacéuticamente aceptable del mismo, Vitamina D y triglicéridos de cadena media o aceites total o parcialmente hidrogenados, que confieren las propiedades físico-químicas deseadas a la formulación sólida para administración oral adecuada para el tratamiento de enfermedades óseas y trastornos del metabolismo del calcio.
MX2015016497A 2013-05-31 2014-05-30 Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d. MX364680B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT106978A PT106978A (pt) 2013-05-31 2013-05-31 Composição sólida oral contendo ácido ibandrónico e vitamina d
PCT/PT2014/000036 WO2014193255A1 (en) 2013-05-31 2014-05-30 Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d

Publications (2)

Publication Number Publication Date
MX2015016497A MX2015016497A (es) 2016-09-08
MX364680B true MX364680B (es) 2019-05-03

Family

ID=50943510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016497A MX364680B (es) 2013-05-31 2014-05-30 Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.

Country Status (16)

Country Link
US (1) US20160106766A1 (es)
EP (1) EP3003383B1 (es)
BR (1) BR112015029897A2 (es)
CL (1) CL2015003468A1 (es)
DK (1) DK3003383T3 (es)
ES (1) ES2705074T3 (es)
HU (1) HUE040666T2 (es)
LT (1) LT3003383T (es)
MA (1) MA38688B1 (es)
MX (1) MX364680B (es)
PL (1) PL3003383T3 (es)
PT (2) PT106978A (es)
RS (1) RS58133B1 (es)
SI (1) SI3003383T1 (es)
TR (1) TR201821157T4 (es)
WO (1) WO2014193255A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056937T2 (hu) 2006-02-03 2022-04-28 Opko Renal Llc A D-vitamin elégtelenség és hiány kezelése 25-hidroxivitamin D2-vel és 25-hidroxivitamin D3-mal
PT2679228T (pt) 2006-06-21 2018-04-16 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
KR101959952B1 (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2015298858A1 (en) 2014-08-07 2017-03-02 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin D
CA3018019A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US20050176685A1 (en) 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100179110A1 (en) * 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
EP1972341A1 (en) 2007-03-23 2008-09-24 Novartis AG Pharmaceutical compositions comprising a bisphosphonate and vitamin D
WO2010075537A1 (en) * 2008-12-23 2010-07-01 Teva Pharmaceutical Industries Ltd. Formulations comprising vitamin d or derivatives thereof
WO2010117346A2 (en) * 2009-04-10 2010-10-14 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility
IT1396937B1 (it) * 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
GB2502032B (en) * 2011-03-02 2015-03-04 D3 Pharma Ltd Stable Vitamin D3 Composition

Also Published As

Publication number Publication date
TR201821157T4 (tr) 2019-02-21
PT3003383T (pt) 2019-01-16
EP3003383B1 (en) 2018-10-03
CL2015003468A1 (es) 2016-07-22
HUE040666T2 (hu) 2019-08-28
EP3003383A1 (en) 2016-04-13
MA38688A1 (fr) 2017-07-31
PT106978A (pt) 2014-12-02
MX2015016497A (es) 2016-09-08
PL3003383T3 (pl) 2019-04-30
LT3003383T (lt) 2019-03-12
WO2014193255A1 (en) 2014-12-04
BR112015029897A2 (pt) 2017-07-25
US20160106766A1 (en) 2016-04-21
SI3003383T1 (sl) 2019-03-29
RS58133B1 (sr) 2019-02-28
ES2705074T3 (es) 2019-03-21
MA38688B1 (fr) 2018-08-31
DK3003383T3 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
MX364680B (es) Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
MY161088A (en) Agonists of gpr40
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
EP2560633A4 (en) INTRAVENOUS COMPOSITIONS OF OMEGA-3 FATTY ACIDS AND METHOD OF USE
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2015001917A (es) Composiciones farmaceuticas de memantina.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
AR091706A1 (es) Formulaciones de laquinimod sin agentes alcalinizantes
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2014130691A3 (en) Pharmaceutical formulations of nitrite and uses thereof
MX2021008536A (es) Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa.
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
IN2014DN09240A (es)
GB2530226A (en) Chewable tablet
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
PL3246032T3 (pl) Kompozycje farmaceutyczne z kwasem zoledronowym, wapniem i witaminą d, odpowiednie do leczenia i/lub profilaktyki chorób metabolicznych kości oraz działań ubocznych spowodowanych terapią, takich jak hipokalcemia
MX2016002139A (es) Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.
NZ713490A (en) Oral suspension for treating eosinophilic esophagitis

Legal Events

Date Code Title Description
FG Grant or registration